Search
Antipain
go.drugbank.com/drugs/DB15251Experimental[A214484, A214487] Antipain was used in 2010 to obtain a crystal structure of the _Leishmania major_ oligopeptidase B (OPB), a serine protease that serves as a virulence factor in trypanosomatids. … Antipain is a serine/cysteine protease inhibitor originally isolated from various strains of actinomycetes.
Milademetan
go.drugbank.com/drugs/DB15257InvestigationalMilademetan is under investigation in clinical trial NCT02319369 (Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingUSL-311
go.drugbank.com/drugs/DB15265InvestigationalUSL-311 is under investigation in clinical trial NCT02765165 (Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma
Synonyms: 2-Pyridinecarboxamide, 6-(hexahydro-4-(1-(1-methylethyl)-4-piperidinyl)-1H-1,4-diazepin-1-yl)-N-4-pyridinyl-, 6-[4-(1-propan-2-ylpiperidin-4-yl)-1,4-diazepan-1-yl]-N-pyridin-4-ylpyridine-2-carboxamideEfgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigational[A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG. … ] The production of IgG autoantibodies against acetylcholine receptors (AChRs) is one of the more common pathophysiological mechanisms behind MG, and results in the destruction of these receptors and a
Categories: Human Immunoglobulin GCrizanlizumab
go.drugbank.com/drugs/DB15271ApprovedInvestigational[L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. … Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease.
Categories: Immunoglobulin GVS-4718
go.drugbank.com/drugs/DB15273InvestigationalVS-4718 is under investigation in clinical trial NCT02215629 (Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia).
Categories: Heterocyclic Compounds, 1-RingTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigationalTebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism
Categories: Bispecific gp100 Peptide-HLA-directed CD3 T Cell EngagerEtamicastat
go.drugbank.com/drugs/DB15288InvestigationalEtamicastat is under investigation in clinical trial NCT02840565 (Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453).
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingHydroquinidine
go.drugbank.com/drugs/DB15300InvestigationalHydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).
Categories: Antiarrhythmics, Class I, Heterocyclic Compounds, 2-Ring2-fluorofucose
go.drugbank.com/drugs/DB15302Investigational2-fluorofucose is under investigation in clinical trial NCT02952989 (A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors).
Synonyms: 2-fluorofucose